Azilsartan Methyl Ester
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574572

CAS#: 147403-52-9

Description: Azilsartan Methyl Ester is a derivative of Azilsartan, an angiotensin II receptor blocker.

Chemical Structure

img
Azilsartan Methyl Ester
CAS# 147403-52-9
Instruction

Theoretical Analysis

MedKoo Cat#: 574572
Name: Azilsartan Methyl Ester
CAS#: 147403-52-9
Chemical Formula: C26H22N4O5
Exact Mass: 470.16
Molecular Weight: 470.480
Elemental Analysis: C, 66.38; H, 4.71; N, 11.91; O, 17.00

Price and Availability

Size Price Availability Quantity
250mg USD 255 2 Weeks
1g USD 470 2 Weeks
5g USD 990 2 Weeks
10g USD 1440 2 Weeks
25g USD 2500 2 Weeks
Bulk inquiry

Synonym: Azilsartan Methyl Ester

IUPAC/Chemical Name: Methyl 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate

InChi Key: PCMXVTVLQVGYLX-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H22N4O5/c1-3-34-25-27-21-10-6-9-20(24(31)33-2)22(21)30(25)15-16-11-13-17(14-12-16)18-7-4-5-8-19(18)23-28-26(32)35-29-23/h4-14H,3,15H2,1-2H3,(H,28,29,32)

SMILES Code: O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NC(ON5)=O)C=C3)=CC=C1)OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 470.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Handley A, Lloyd E, Roberts A, Barger B. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clin Exp Hypertens. 2016;38(2):180-8. doi: 10.3109/10641963.2015.1081213. Epub 2016 Jan 28. PubMed PMID: 26817604.

2: White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Jan 12. [Epub ahead of print] PubMed PMID: 26766564.

3: Webb NJ, Wells T, Tsai M, Zhao Z, Juhasz A, Dudkowski C. Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults. Eur J Clin Pharmacol. 2016 Jan 4. [Epub ahead of print] PubMed PMID: 26725367.

4: Bramlage P, Schmieder RE, Gitt AK, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Potthoff SA; EARLY Registry Group. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8. PubMed PMID: 26686682; PubMed Central PMCID: PMC4684935.

5: Tsai MC, Wu J, Kupfer S, Vakilynejad M. Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients with Stage 2 Hypertension. J Clin Pharmacol. 2015 Dec 3. doi: 10.1002/jcph.684. [Epub ahead of print] PubMed PMID: 26632101.

6: Harrell RE, Karim A, Zhang W, Dudkowski C. Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects. Clin Pharmacokinet. 2015 Oct 27. [Epub ahead of print] PubMed PMID: 26507722.

7: Kuze Y, Kogame A, Jinno F, Kondo T, Asahi S. Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 15;1001:174-81. doi: 10.1016/j.jchromb.2015.07.047. Epub 2015 Jul 30. PubMed PMID: 26279009.

8: Swain D, Patel PN, Palaniappan I, Sahu G, Samanthula G. Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium. Rapid Commun Mass Spectrom. 2015 Aug 15;29(15):1437-47. doi: 10.1002/rcm.7235. PubMed PMID: 26147484.

9: Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Senges J, Gitt AK; EARLY Registry Group. Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. J Clin Hypertens (Greenwich). 2015 Dec;17(12):947-53. doi: 10.1111/jch.12603. Epub 2015 Jun 24. PubMed PMID: 26105590.

10: Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. J Clin Hypertens (Greenwich). 2015 Mar;17(3):183-92. doi: 10.1111/jch.12474. Epub 2015 Jan 24. PubMed PMID: 25619410.

11: Ebeid WM, Elkady EF, El-Zaher AA, El-Bagary RI, Patonay G. Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics. Anal Bioanal Chem. 2014 Oct;406(26):6701-12. doi: 10.1007/s00216-014-8085-0. Epub 2014 Sep 5. PubMed PMID: 25190009.

12: Abdelsaid M, Coucha M, Ergul A. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. Transl Res. 2014 Nov;164(5):424-32. doi: 10.1016/j.trsl.2014.06.003. Epub 2014 Jun 17. PubMed PMID: 24999268; PubMed Central PMCID: PMC4250409.

13: Baker WL, Nigro SC, White WB. Efficacy of azilsartan medoxomil with chlorthalidone in hypertension. Expert Rev Cardiovasc Ther. 2014 Jul;12(7):791-8. doi: 10.1586/14779072.2014.924853. Epub 2014 Jun 2. Review. PubMed PMID: 24881461.

14: Ebeid WM, Elkady EF, El-Zaher AA, El-Bagary RI, Patonay G. Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals. Anal Chem Insights. 2014 May 7;9:33-40. doi: 10.4137/ACI.S13768. eCollection 2014. PubMed PMID: 24855334; PubMed Central PMCID: PMC4022702.

15: Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr;19(2):90-7. doi: 10.1097/MBP.0000000000000027. PubMed PMID: 24445723; PubMed Central PMCID: PMC3966914.

16: Barrios V, Escobar C. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? Expert Opin Pharmacother. 2013 Nov;14(16):2249-61. doi: 10.1517/14656566.2013.834887. Epub 2013 Sep 26. Review. PubMed PMID: 24070321.

17: Lastra G, Santos FR, Hooshmand P, Hooshmand P, Mugerfeld I, Aroor AR, Demarco VG, Sowers JR, Henriksen EJ. The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle. Cardiorenal Med. 2013 Jul;3(2):154-164. Epub 2013 Jun 25. PubMed PMID: 23922555; PubMed Central PMCID: PMC3721134.

18: Pierini D, Anderson KV. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. Ann Pharmacother. 2013 May;47(5):694-703. doi: 10.1345/aph.1R618. Epub 2013 Apr 12. PubMed PMID: 23585646.

19: Preston RA, Karim A, Dudkowski C, Zhao Z, Garg D, Lenz O, Sica DA. Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment. Clin Pharmacokinet. 2013 May;52(5):347-58. doi: 10.1007/s40262-013-0044-y. PubMed PMID: 23575872.

20: Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug;27(8):479-86. doi: 10.1038/jhh.2013.6. Epub 2013 Mar 21. PubMed PMID: 23514842; PubMed Central PMCID: PMC3715765.